DE60333628D1 - Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie - Google Patents

Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie

Info

Publication number
DE60333628D1
DE60333628D1 DE60333628T DE60333628T DE60333628D1 DE 60333628 D1 DE60333628 D1 DE 60333628D1 DE 60333628 T DE60333628 T DE 60333628T DE 60333628 T DE60333628 T DE 60333628T DE 60333628 D1 DE60333628 D1 DE 60333628D1
Authority
DE
Germany
Prior art keywords
treatment
medicament
prevention
amyloid polyneuropathy
amyloidosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60333628T
Other languages
English (en)
Inventor
Hirofumi Kai
Yukio Ando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nipro Corp
Original Assignee
Nipro Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nipro Corp filed Critical Nipro Corp
Application granted granted Critical
Publication of DE60333628D1 publication Critical patent/DE60333628D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60333628T 2002-05-14 2003-05-13 Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie Expired - Lifetime DE60333628D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002137944 2002-05-14
PCT/JP2003/005963 WO2003094934A1 (fr) 2002-05-14 2003-05-13 Médicament pour prévenir et traiter l'amyloïdose

Publications (1)

Publication Number Publication Date
DE60333628D1 true DE60333628D1 (de) 2010-09-16

Family

ID=29416833

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60333628T Expired - Lifetime DE60333628D1 (de) 2002-05-14 2003-05-13 Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie

Country Status (7)

Country Link
US (1) US20060134228A1 (de)
EP (1) EP1504762B1 (de)
CN (1) CN100457122C (de)
AT (1) ATE476188T1 (de)
AU (1) AU2003235261A1 (de)
DE (1) DE60333628D1 (de)
WO (1) WO2003094934A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1819354T3 (da) * 2004-08-26 2011-09-12 Biocrine Ab Fremgangsmåder og forbindelser til behandling af diabetes
US10398729B2 (en) * 2012-02-14 2019-09-03 Kenneth O. Russell Method for treating Alzheimer's disease
WO2010030203A1 (en) * 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
CN103833628B (zh) * 2014-02-21 2016-05-11 河北富格药业有限公司 一种吡啶甲酸铬的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
GB9300920D0 (en) * 1993-01-19 1993-03-10 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
KR960037692A (ko) * 1995-04-13 1996-11-19 김광희 피콜린산-크롬 복합물의 새로운 제조방법
US5614224A (en) * 1995-04-20 1997-03-25 Womack; Rick W. Nutritional supplement for diabetics
US6329361B1 (en) * 1995-05-12 2001-12-11 Nutrition 21 High-dose chromic picolinate treatment of type II diabetes
CN1189776A (zh) * 1995-05-12 1998-08-05 营养21 大剂量给药用于治疗ⅱ型糖尿病的三吡啶甲酸铬
CA2257279A1 (en) * 1996-06-06 1997-12-11 Reuven Sandyk Compositions and method which retard the aging process and which improve age-related disease conditions
EP1006794B1 (de) 1997-03-12 2007-11-28 Robert W. Esmond Verfahren zur behandlung oder prävention der alzheimerischen krankheit
US5888553A (en) * 1997-04-08 1999-03-30 Infinity, Inc. Non-steroidal anabolic composition
HUP0003713A2 (hu) * 1997-08-08 2001-04-28 Nutrition 21 Króm és biotin tartalmú gyógyászati készítmény II típusú diabétesz kezelésére
US6143301A (en) * 1998-08-28 2000-11-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US5980905A (en) * 1998-08-28 1999-11-09 Ambi Inc. Chromium polynicotinate compositions and uses thereof
WO2000012102A1 (en) * 1998-08-31 2000-03-09 Proteotech, Inc. Blended compositions for treatment of alzheimer's disease and other amyloidoses
EP1113804A2 (de) * 1998-09-17 2001-07-11 Akesis Pharmaceuticals, Inc. Kombinationen des chroms oder des vanadiums mit antidiabetika für glukosemetabolismusstörungen
WO2000041686A1 (en) * 1999-01-12 2000-07-20 Seymour Ehrenpreis Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
US20050214384A1 (en) * 2002-04-23 2005-09-29 Vijaya Juturu Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance

Also Published As

Publication number Publication date
CN100457122C (zh) 2009-02-04
EP1504762A1 (de) 2005-02-09
AU2003235261A1 (en) 2003-11-11
CN1652803A (zh) 2005-08-10
EP1504762B1 (de) 2010-08-04
EP1504762A4 (de) 2008-03-26
ATE476188T1 (de) 2010-08-15
US20060134228A1 (en) 2006-06-22
WO2003094934A1 (fr) 2003-11-20

Similar Documents

Publication Publication Date Title
AU2003256755A8 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DE60228761D1 (de) Pharmazeutische zusammensetzung (kit) enthaltend dihydropyridinonverbindungen und eine verbindung mit immunmodulatorischer (oder antiinflammatorischer) wirkung und ihre verwendung
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
BR0116832A (pt) Produto desodorante, método cosmético e método de fabricação de composição desodorante
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
ATE340568T1 (de) Verwendung einer pharmazeutischen formulierung enthaltend milchsäure oder laktat und kalium zur behandlung von hirnödem und verletzungen des gehirns
ATE318606T1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
BRPI0508333A (pt) uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit
DE69231955D1 (de) Verwendung von N-(2,6-Dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamid zur Behandlung von Demenz
DE60333628D1 (de) Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
DE60231969D1 (de) sPLA2-INHIBITOREN ZUR BEHANDLUNG VON ARTERIOSKLEROSE
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
ATE346597T1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
ATE410172T1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
BR0317947A (pt) Inibidores de quinurenina 3-hidroxilase para o tratamento de diabetes
WO2001070683A3 (en) 3-substituted-4-pyrimidone derivatives
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE333897T1 (de) Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
EP1496742A4 (de) Verwendung von nichtantibakteriellen tetrazyklin-analoga und ihren formulierungen für die behandlung von bakteriellen exotoxinen
ATE108063T1 (de) Heilmittel zur behandlung von toxoplasmose.
DE69932434D1 (de) Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten